Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Christopher Peetz Sells 9,108 Shares of Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz sold 9,108 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $103.30, for a total transaction of $940,856.40. Following the sale, the chief executive officer directly owned 160,294 shares in the company, valued at approximately $16,558,370.20. The trade was a 5.38% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Christopher Peetz also recently made the following trade(s):

• On Monday, January 26th, Christopher Peetz sold 6,831 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $96.19, for a total value of $657,073.89.
• On Thursday, January 22nd, Christopher Peetz sold 7,098 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $93.33, for a total value of $662,456.34.

Mirum Pharmaceuticals Stock Performance

NASDAQ MIRM opened at $105.45 on Wednesday. The stock has a market cap of $5.42 billion, a PE ratio of -122.61 and a beta of 0.49. The company has a current ratio of 3.31, a quick ratio of 3.16 and a debt-to-equity ratio of 1.06. Mirum Pharmaceuticals, Inc. has a twelve month low of $36.88 and a twelve month high of $105.64. The stock has a fifty day simple moving average of $81.60 and a 200-day simple moving average of $73.33.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.15. The firm had revenue of $133.01 million for the quarter, compared to analyst estimates of $130.11 million. Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 16.47%. Mirum Pharmaceuticals’s revenue was up 47.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.30) EPS. Equities analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in MIRM. CWM LLC increased its position in shares of Mirum Pharmaceuticals by 30.8% in the 3rd quarter. CWM LLC now owns 683 shares of the company’s stock valued at $50,000 after purchasing an additional 161 shares during the last quarter. Legal & General Group Plc grew its stake in shares of Mirum Pharmaceuticals by 0.4% during the second quarter. Legal & General Group Plc now owns 43,010 shares of the company’s stock worth $2,189,000 after purchasing an additional 176 shares in the last quarter. MCF Advisors LLC grew its stake in shares of Mirum Pharmaceuticals by 76.4% during the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after purchasing an additional 185 shares in the last quarter. Teacher Retirement System of Texas increased its holdings in Mirum Pharmaceuticals by 2.2% in the second quarter. Teacher Retirement System of Texas now owns 9,903 shares of the company’s stock valued at $504,000 after buying an additional 215 shares during the last quarter. Finally, Jones Financial Companies Lllp increased its holdings in Mirum Pharmaceuticals by 34.0% in the third quarter. Jones Financial Companies Lllp now owns 957 shares of the company’s stock valued at $70,000 after buying an additional 243 shares during the last quarter.

Wall Street Analyst Weigh In

A number of research firms have commented on MIRM. Leerink Partners set a $100.00 price target on Mirum Pharmaceuticals in a research note on Wednesday, December 10th. TD Cowen reaffirmed a “buy” rating on shares of Mirum Pharmaceuticals in a research report on Monday, January 12th. Raymond James Financial reiterated a “strong-buy” rating and set a $110.00 price target on shares of Mirum Pharmaceuticals in a research note on Thursday, December 11th. Wall Street Zen raised shares of Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 17th. Finally, Citizens Jmp upped their target price on shares of Mirum Pharmaceuticals from $95.00 to $140.00 and gave the stock a “market outperform” rating in a research note on Friday, December 19th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $107.25.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.